Comprehensive Report on DCR-CM2 (Lepodisiran; LY3819469): An Investigational siRNA Therapeutic for Elevated Lipoprotein(a)

I. Introduction to DCR-CM2 (Lepodisiran)

A. Overview of DCR-CM2 (Lepodisiran) as an Investigational Therapeutic

Lepodisiran, identified by the development codes DCR-CM2 and LY3819469, is an investigational therapeutic agent belonging to the class of small interfering RNAs (siRNAs).[1] It is specifically engineered for the treatment of hyperlipidemia, with a primary focus on reducing elevated plasma concentrations of lipoprotein(a) [Lp(a)].[1] Lp(a) is a genetically determined lipoprotein particle recognized as an independent causal risk factor for atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve stenosis, and overall cardiovascular morbidity and mortality.[1] Elevated levels of Lp(a) are prevalent, affecting an estimated 20-25% of the global population.[4] The existence of multiple development codes, DCR-CM2 and LY3819469, likely reflects the progression of the drug's development, originating from Dicerna Pharmaceuticals (where "DCR-" prefixes are common for pipeline candidates) and subsequently advancing under Eli Lilly and Company (where "LY" prefixes are characteristic).[13] This transition from a smaller biotechnology company, often specializing in innovative platform technologies, to a large pharmaceutical firm for extensive late-stage clinical trials and potential commercialization is a well-established pattern in the pharmaceutical industry, particularly for therapeutics targeting large patient populations and requiring substantial investment in outcomes studies.

B. Synonyms, Chemical Class, and Key Identifiers